Cargando…

Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis

BACKGROUND: There are conflicting reports on the results of several of the latest clinical trials related to the use of baricitinib in the management of COVID-19 patients. The aim of the current systematic review and meta-analysis was to evaluate the efficacy of baricitinib in COVID-19 patients. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manoharan, Sivananthan, Ying, Lee Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477792/ https://www.ncbi.nlm.nih.gov/pubmed/36150282 http://dx.doi.org/10.1016/j.rmed.2022.106986

Ejemplares similares

Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
por: Manoharan, Sivananthan, et al.
Publicado: (2022)

Epstein Barr Virus Reactivation during COVID-19 Hospitalization Significantly Increased Mortality/Death in SARS-CoV-2(+)/EBV(+) than SARS-CoV-2(+)/EBV(−) Patients: A Comparative Meta-Analysis
por: Manoharan, Sivananthan, et al.
Publicado: (2023)

Baricitinib en el tratamiento de infección por SARS-CoV-2
por: Gutiérrez-Lorenzo, Marta, et al.
Publicado: (2020)

Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques
por: Hoang, Timothy N., et al.
Publicado: (2020)

Does hand hygiene reduce SARS-CoV-2 transmission?
por: Yang, Chao
Publicado: (2020)

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques
por: Hoang, Timothy N., et al.
Publicado: (2021)

Reply to “Does hand hygiene reduce SARS-CoV-2 transmission?”
por: Lai, Tracy H. T., et al.
Publicado: (2020)

Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
por: Akbarzadeh-Khiavi, Mostafa, et al.
Publicado: (2021)

507. Impact of Baricitinib on Outcomes in Patients Treated with Remdesivir and Dexamethasone for SARS-CoV-2 Pneumonia: A Retrospective Cohort Study
por: Dea, Lauren, et al.
Publicado: (2021)

The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus
por: Liu, Ying, et al.
Publicado: (2021)

Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude?
por: Arias-Reyes, Christian, et al.
Publicado: (2020)

Does SARS-CoV-2 re-infection depend on virus variant?
por: Gautret, Philippe, et al.
Publicado: (2021)

Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients
por: Bayat, Vafa, et al.
Publicado: (2021)

Does SARS-CoV-2 Bind to Human ACE2 More Strongly Than Does SARS-CoV?
por: Nguyen, Hoang Linh, et al.
Publicado: (2020)

Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality
por: Mehta, Puja, et al.
Publicado: (2022)

The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects
por: Al-Salihi, Karima A., et al.
Publicado: (2021)

Does vitamin D status impact mortality from SARS-CoV-2 infection?()
por: Marik, Paul E., et al.
Publicado: (2020)

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
por: Kalil, Andre C, et al.
Publicado: (2021)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
por: Abdelrahman, Zeinab, et al.
Publicado: (2020)

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro
por: Dong, Jie, et al.
Publicado: (2022)

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
por: Richardson, Peter, et al.
Publicado: (2020)

Altitude does not protect against SARS‐CoV‐2 infections and mortality due to COVID‐19
por: Cardenas, Laura, et al.
Publicado: (2021)

Is It Still Relevant to Discover New ACE Inhibitors from Natural Products? YES, but Only with Comprehensive Approaches to Address the Patients’ Real Problems: Chronic Dry Cough and Angioedema
por: Manoharan, Sivananthan
Publicado: (2023)

Tropism of SARS-CoV-2, SARS-CoV, and Influenza Virus in Canine Tissue Explants
por: Bui, Christine H T, et al.
Publicado: (2021)

The recency and geographical origins of the bat viruses ancestral to SARS-CoV and SARS-CoV-2
por: Pekar, Jonathan E., et al.
Publicado: (2023)

SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets
por: Huang, Ying, et al.
Publicado: (2022)

Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection
por: Moreno-García, Estela, et al.
Publicado: (2021)

Treatment with the senolytics dasatinib/quercetin reduces SARS‐CoV‐2‐related mortality in mice
por: Pastor‐Fernández, Andrés, et al.
Publicado: (2023)

N-dihydrogalactochitosan reduces mortality in a lethal mouse model of SARS-CoV-2
por: Weiss, Christopher M., et al.
Publicado: (2023)

SARS-CoV-2, the autoimmune virus
por: Halpert, Gilad, et al.
Publicado: (2020)

Is SARS-CoV-2 an oncogenic virus?
por: Gómez-Carballa, Alberto, et al.
Publicado: (2022)

Does lopinavir really inhibit SARS-CoV-2?
por: Cattaneo, Dario, et al.
Publicado: (2020)

Does ocular tissue contain SARS CoV-2?
por: Biswas, Jyotirmay, et al.
Publicado: (2021)

What SARS-CoV-2 does to our brains
por: Aschman, Tom, et al.
Publicado: (2022)

How Does SARS-CoV-2 Fragment the QRS?
por: Finsterer, Josef
Publicado: (2022)

Recent Progresses in Electrochemical DNA Biosensors for SARS-CoV-2 Detection
por: Mei, Yanqiu, et al.
Publicado: (2022)

Predictors of all‐cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS‐CoV‐2
por: Hamilton, Mackenzie A., et al.
Publicado: (2022)

Does maternal SARS-CoV-2 infection or SARS-CoV-2 vaccination trigger an inflammatory response in the fetus?
por: Alhousseini, Ali, et al.
Publicado: (2022)

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
por: Sada, Mitsuru, et al.
Publicado: (2020)

The envelope proteins from SARS-CoV-2 and SARS-CoV potently reduce the infectivity of human immunodeficiency virus type 1 (HIV-1)
por: Henke, Wyatt, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u6ul31lh7b12udiproaf6h4gi5